Abstract:Objective To investigate the efficacy of sunitinib in the treatment of patients with imatinibresistant advanced gastrointestinal stromal tumor (GIST).Methods The clinical data of 45 patients with imatinib-resistant advanced GIST who received the treatment of sunitinib (37.5 mg/d) at the First Affiliated Hospital of Sun Yat-Sen University from March 2008 to June 2012 were retrospectively analyzed.The mutation of c-kit and platelet-derived growth factor receptor α (PDGFRα) was detected,and the efficacy of imatinib was assessed after the treatment for 3 months,and factors influencing the survival were analysed.The survival rate was calculated using the Kaplan-Meier method,survival analysis was done using the one-way analysis of variance,and multivariate analysis was done using the COX regression model.Results The median time of treatment with sunitinib for the 45 patients was 11.0 months (range,4-37 months).The complete remission rate,partial response rate,rate of stabilized condition and disease progression rate were 15.6％ (7/45),8.9％ (4/45),46.7％ (21/45) and 28.9％ (13/45) after the treatment with sunitinib for 3 months.All the patients with clinical (imaging) complete remission received surgery for metastatic lesions or B-ultrasound guided ablation for single liver metastasis before the treatment with sunitinib.The most common grade 3 or 4 adverse reactions of sunitinib were hand-foot syndrome and anemia.C-kit and PDGFRα mutational analysis were carried out.C-kit exon 9 mutation was detected in 9 patients,c-kit exon 11 mutation in 21 patients,and no mutation was detected in 12 patients.The median progression-free survival time was 8.0 months (range,4.1-11.9 months),and the median overall survival time was 25.0 months (range,13.4-36.6 months).The results of univariate analysis showed that the primary lesion sites and mutational status of primary lesions were factors influencing the progression-free survival and overall survival (x2=5.967,6.622 ; 7.965,8.765,P ＜ 0.05).The results of multivariate analysis showed that only the mutational status of c-kit of primary lesions was the independent factor influencing the progression-free survival and overall survival (Wald =6.540,7.205,P ＜ 0.05).The progression-free survival and overall survival of patients with c-kit exon 9 mutation and patients with no gene mutation were significantly longer than patients with c-kit exon 11 mutation (x2 =7.965,8.765,P ＜ 0.05).Conclusion Sunitinib with a dosage of 37.5 mg/d could effectively treat patients with imatinib-resistant advanced GIST.A better survival is observed in patients with c-kit exon 9 mutation or with no gene mutation when compared with patients with c-kit exon 11 mutation.

Efficacy and safety of Imatinib in the 78 patients with advanced melanoma harboring KIT mutation

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence from a Retrospective Study

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Phase Ii, Open-Label, Single-Arm Trial Of Imatinib Mesylate In Patients With Metastatic Melanoma Harboring C-Kit Mutation Or Amplification

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial)

A Phase II Randomized Study of Adjuvant Imatinib Versus High-Dose Interferon Alpha-2B for Resected High-Risk C-Kit Mutated Melanoma.

PhaseⅡ randomized trial comparing imatinib with high-dose interferon alpfa-2b as adjuvant therapy for high-risk melanoma patients with c-Kit mutations

Response To Sunitinib In Chinese Kit-Mutated Metastatic Mucosal Melanoma

815P A Single-Arm, Phase II Clinical Study of Imatinib Mesylate/toripalimab Combo in Patients (pts) with Advanced Melanoma Harboring C-Kit Mutation or Amplification

Imatinib Versus Interferon As Adjuvant Therapy in a Phase II Study in Patients with Highrisk C-Kit Mutated Melanoma.

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Clinical Analysis of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor

Efficacy of imatinib in patients with unresectable or metastatic gastrointestinal stromal tumors and its adverse effects

Efficacy and safety of imatinib on treatment for patients with advanced gastrointestinal stromal tumors

Efficacy and Safety of the Imatinib in the Treatment of 73 Gastrointestinal Stromal Tumors

Application of Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumor

Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumors

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis

Mtor Pathway Activation in Kit-Mutated Melanoma with Acquired Imatinib Resistance.